Is ultrasound axillary staging less accurate in invasive lobular breast cancer than in ductal breast cancer?
© Sankaye et al.; licensee BioMed Central Ltd. 2012
Published: 9 November 2012
To identify whether axillary US is less accurate in invasive lobular breast cancer than in ductal breast cancer.
Randomised cohorts of screening and symptomatic patients were retrospectively identified from histology records of 2010/11. Axillary US of 65 patients with primary breast cancers (BC) from each group of invasive lobular cancer (ILC) and invasive ductal cancer (IDC) were reviewed. Preoperative US-guided needle biopsy sampling was performed on abnormal lymph nodes (LN).
Preoperative US detection of node-positive disease
Abnormal US LN appearance
False negative rate for axillary US biopsy
0.73(0.51 to 0.88)
0.73(0.48 to 0.89)
0.83 (0.68 to 0.92)
0.93 (0.8 to 0.98)
US positive predictive value
0.70 (0.48 to 0.86)
0.82 (0.55 to 0.95)
The previous literature on this topic is inconclusive. Some authors have suggested axillary ultrasound in ILC may be less accurate than in IDC, with a higher false-negative axillary assessment rate. Another study concluded that axillary US accuracy rates in ILC were comparable with previous published studies of IDC, used FNA in all cases. We specifically compared accuracy rates of preoperative axillary staging between ILC and IDC in own institution, with 14G needle biopsy as the procedure of choice to sample abnormal nodes. We found that there is no statistical difference in accuracy in US axillary staging between ILC and IDC.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.